Oncolytics Biotech (ONCY) Cash from Financing Activities (2009 - 2025)
Oncolytics Biotech (ONCY) posted quarterly Cash from Financing Activities of $14.1 million for Q4 2025, up 490.1% year-over-year from $2.4 million in Q4 2024, and up 369.09% quarter-over-quarter from $3.0 million in Q3 2025.
Oncolytics Biotech (ONCY) Cash from Financing Activities (2009 - 2025) Analysis & Trends
Oncolytics Biotech (ONCY) has reported Cash from Financing Activities for 17 consecutive years, with $14.1 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Cash from Financing Activities rose 490.1% year-over-year to $14.1 million; the TTM figure through Dec 2025 stood at $25.1 million (up 420.96% YoY), while the FY2025 annual figure was $14.1 million, up 180.83% from the prior year.
- Cash from Financing Activities improved to $14.1 million in Q4 2025 per ONCY's latest filing, from $3.0 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $19.9 million in Q1 2021 and bottomed at -$126818.2 in Q3 2024.
- Historically, Cash from Financing Activities has averaged $4.5 million across 5 years, with a median of $2.9 million in 2023.
- Annual changes were most pronounced in 2021 — Cash from Financing Activities slumped 102.42% — and 2022, when it jumped 10505.18%.
- Oncolytics Biotech's Cash from Financing Activities stood at -$41560.5 in 2021, then soared by 10505.18% to $4.3 million in 2022, then tumbled by 70.41% to $1.3 million in 2023, then soared by 86.8% to $2.4 million in 2024, then jumped by 490.1% to $14.1 million in 2025.
- Business Quant data shows ONCY's Cash from Financing Activities at $14.1 million in Q4 2025, $3.0 million in Q3 2025, and $3.9 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Oncolytics Biotech | 101.16 Mn | 101.16 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 14.10 Mn |
| Dec 31, 2025 | 14.10 Mn |
| Sep 30, 2025 | 3.01 Mn |
| Sep 30, 2025 | 3.01 Mn |
| Jun 30, 2025 | 3.88 Mn |
| Jun 30, 2025 | 3.88 Mn |
| Mar 31, 2025 | 4.10 Mn |
| Mar 31, 2025 | 4.10 Mn |
| Dec 31, 2024 | 2.39 Mn |
| Dec 31, 2024 | 2.39 Mn |
| Sep 30, 2024 | -126,818.24 |
| Sep 30, 2024 | -126,818.24 |
| Jun 30, 2024 | 1.44 Mn |
| Jun 30, 2024 | 1.44 Mn |
| Mar 31, 2024 | 1.11 Mn |
| Mar 31, 2024 | 1.11 Mn |
| Dec 31, 2023 | 1.28 Mn |
| Dec 31, 2023 | 1.28 Mn |
| Sep 30, 2023 | 15.88 Mn |
| Sep 30, 2023 | 15.88 Mn |